公开(公告)号：US11529408B2

公开(公告)日：2022-12-20

申请号：US17881131

申请日：2022-08-04

申请人： Etubics Corporation

发明人： Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle, III

IPC分类号： A61K39/12 ,  A61K38/20 ,  C07K14/005 ,  A61K38/19 ,  C07K14/71 ,  A61K39/00 ,  A61K39/21 ,  A61P35/00 ,  C12N15/86 ,  C07K14/705 ,  A61K39/235 ,  A61K38/21

摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US11524068B2

公开(公告)日：2022-12-13

申请号：US16910284

申请日：2020-06-24

申请人： Zoetis Services LLC

发明人： Cassius McAllister Tucker ,  John David Haworth

IPC分类号： A61K39/175 ,  A61K39/295 ,  A61K39/00 ,  A61K39/38 ,  A61K39/235 ,  A61K39/02 ,  A61K39/12 ,  A61K39/155 ,  A61K39/23 ,  C07K14/005 ,  C12N7/00

摘要： This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.

公开(公告)号：US20220233718A1

公开(公告)日：2022-07-28

申请号：US17587973

申请日：2022-01-28

申请人： Genemedicine Co., Ltd.

发明人： Chae Ok YUN ,  Hyo Min AHN

IPC分类号： A61K48/00 ,  A61K38/20 ,  A61K39/235 ,  A61P35/00

摘要： An oncolytic adenovirus co-expressing interleukin (IL-12) and shVEGF and a composition for enhancing an anticancer effect are disclosed. The inventors confirmed that, when VEGF suppression and IL-12 expression are co-expressed in immunocompetent murine melanoma or kidney cancer models, an immune function is restored and an anticancer effect is improved. Particularly, it has been revealed that such an improved anticancer effect is associated with an increase in anticancer immunity, an increase in Thl cytokines and prevention of tumor-induced thymic atrophy, and therefore the applicability of a gene delivery system co-expressing IL-12 and shVEGF to cancer gene therapy was identified for the first time.

公开(公告)号：US11376316B2

公开(公告)日：2022-07-05

申请号：US15265709

申请日：2016-09-14

申请人： Etubics Corporation

发明人： Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle

IPC分类号： A61K39/12 ,  A61K39/21 ,  C12N15/86 ,  A61K39/00 ,  A61P35/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/235 ,  C07K14/005 ,  C07K14/705 ,  C07K14/71

摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US11344613B2

公开(公告)日：2022-05-31

申请号：US13622263

申请日：2012-09-18

申请人： Etubics Corporation

发明人： Joseph P. Balint ,  Frank R. Jones ,  Richard B. Gayle, III

IPC分类号： A61K39/12 ,  A61K39/21 ,  C12N15/86 ,  A61K39/00 ,  A61P35/00 ,  A61K38/19 ,  A61K38/20 ,  A61K38/21 ,  A61K39/235 ,  C07K14/005 ,  C07K14/705 ,  C07K14/71

摘要： Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

公开(公告)号：US20220152111A1

公开(公告)日：2022-05-19

申请号：US17586698

申请日：2022-01-27

申请人： AlloVir Inc. ,  Baylor College of Medicine

发明人： Rainer Ludwig KNAUS ,  Katy Rebecca NEWTON ,  Juan VERA ,  Ann LEEN ,  Cliona ROONEY ,  John R. WILSON

IPC分类号： A61K35/17 ,  C12M1/04 ,  A61K39/12 ,  C12N5/0783 ,  A61K39/245 ,  A61K39/235 ,  C12N7/00

摘要： An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, for example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.

公开(公告)号：US11141477B2

公开(公告)日：2021-10-12

申请号：US17214885

申请日：2021-03-28

申请人： Altimmune, Inc

发明人： De-chu C Tang

IPC分类号： A61K39/235 ,  A61K39/215 ,  C12N7/00 ,  A61K39/00 ,  A61K39/07 ,  A61K9/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/39

摘要： The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

公开(公告)号：US20210283245A1

公开(公告)日：2021-09-16

申请号：US16883263

申请日：2020-05-26

申请人： ImmunityBio, Inc. ,  GlobeImmune, Inc

发明人： Kayvan Niazi ,  Thomas King

IPC分类号： A61K39/235 ,  C07K14/165 ,  C12N1/16

摘要： Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

公开(公告)号：US20210260183A1

公开(公告)日：2021-08-26

申请号：US17214885

申请日：2021-03-28

申请人： Altimmune, Inc

发明人： De-chu C Tang

IPC分类号： A61K39/215 ,  A61K39/07 ,  C12N7/00 ,  A61K9/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K39/155 ,  A61K39/39 ,  A61K39/235

摘要： The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).

公开(公告)号：US20210046177A1

公开(公告)日：2021-02-18

申请号：US16964348

申请日：2019-01-25

申请人： NANTCELL, INC. ,  NANTBIO, INC. ,  NANT HOLDINGS IP, LLC

发明人： Adrian E. RICE ,  Frank R. JONES ,  Kayvan NIAZI ,  Shahrooz RABIZADEH ,  Patrick SOON-SHIONG

IPC分类号： A61K39/235 ,  A61P35/00 ,  C12N15/86 ,  C12N15/11 ,  C12N15/10

摘要： Methods and compositions for generating enhanced immune responses using adenovirus vectors that encode for an antigen and calreticulin, which serves as an immunologic adjuvant.